JTZ 951

Drug Profile

JTZ 951

Alternative Names: JTZ-951

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Class Antianaemics
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 08 Nov 2017 Japan Tobacco initiates enrolment in a phase III trial for Anaemia (chronic kidney disease patients not requiring dialysis) in Japan (JapicCTI-173699)
  • 08 Nov 2017 Japan Tobacco initiates enrolment in a phase III trial for Anaemia (chronic kidney disease patients receiving maintenance haemodialysis) in Japan (JapicCTI-173700)
  • 06 Nov 2017 Japan Tobacco initiates enrolment in a phase III trial for Anaemia (In ESA naive patients with chronic kidney disease receiving haemodialysis) in Japan, before November 2017 (JapicCTI-173702)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top